16,614 Shares in IQVIA Holdings Inc. $IQV Purchased by Empowered Funds LLC

Key Points

• Empowered Funds LLC initiated a 16,614-share position in IQVIA Holdings valued at approximately $3.21 million. Institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting $3.15 in earnings per share and $4.37 billion in revenue, up 8.7% year over year. The company also authorized a $2 billion share-repurchase program, covering up to 6.8% of outstanding shares.
• Analysts maintain a generally positive view, with one Strong Buy, 13 Buy and three Hold ratings, resulting in a “Moderate Buy” consensus and an average price target of $241.88.

Empowered Funds LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,614 shares of the medical research company's stock, valued at approximately $3,210,000.

A number of other hedge funds have also made changes to their positions in the stock. BlackRock Inc. purchased a new position in IQVIA during the second quarter valued at approximately $2,811,292,000. Boston Partners purchased a new stake in IQVIA in the 3rd quarter worth approximately $676,698,000. Norges Bank acquired a new stake in shares of IQVIA during the 4th quarter valued at $497,445,000. Victory Capital Management Inc. grew its holdings in shares of IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company's stock valued at $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of IQVIA in the second quarter worth $240,911,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last ninety days. 1.70% of the stock is owned by company insiders.

IQVIA Stock Performance

Shares of NYSE IQV opened at $258.39 on Wednesday. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $265.25. The company has a market cap of $42.53 billion, a P/E ratio of 32.06, a P/E/G ratio of 2.23 and a beta of 1.18. The business's 50 day moving average is $225.75 and its two-hundred day moving average is $190.73. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business's revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

Analyst Ratings Changes

A number of analysts have issued reports on IQV shares. HSBC reiterated a "buy" rating and issued a $240.00 target price on shares of IQVIA in a research note on Monday, July 6th. Barclays restated an "overweight" rating on shares of IQVIA in a research note on Tuesday, July 28th. Mizuho lifted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. TD Cowen upped their price objective on shares of IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $241.88.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source